PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps Oct 07, 2022

Show notes

Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners’ knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

Norman E. Lepor, MD, FACC, FAHA, FSCAI - Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events? Oct 07, 2022

Show notes

Go online to PeerView.com/TVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hyperlipidemia management examines the evidence for PCSK9-targeting therapies to prevent primary and secondary cardiovascular (CV) events. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of CV events; Recognize novel mechanisms of action and recent clinical evidence on approved and emerging investigational lipid-lowering therapies that target PCSK9; and Develop treatment protocols using appropriate lipid-lowering therapy including available and emerging agents, alone or in combination, for providing long-term LDL-C reduction and improving adherence.

Marcia S. Brose, MD, PhD, FASCO - Optimizing NTRK Fusion Testing and TRK Inhibition in Thyroid Cancer: Team-Based Approaches for Enhanced Outcomes Oct 04, 2022

Show notes

Go online to PeerView.com/QKA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this inExchange from PeerView, a multidisciplinary team of experts from oncology, endocrinology, and pathology discuss the advantages of a team-based approach to NTRK fusion testing and TRK inhibition in thyroid cancer. In this 30-minute learning opportunity, you’ll hear how endocrinologists can lead the interprofessional charge to enhance outcomes by optimizing NTRK fusion testing and TRK-targeted therapy. This presentation covers the rationale, science, and evidence, and presents actionable strategies for putting the data into practice for patients with fusion-positive thyroid cancer. Upon completion of this activity, participants should be better able to: Explain the rationale for testing for NTRK fusions in patients with thyroid cancer, including their role in disease development and progression and impact on prognosis and treatment algorithms; Cite current efficacy and safety evidence on TRK-targeted therapies in patients with NTRK fusion–positive thyroid cancers; Implement practical strategies to ensure patients with thyroid cancer receive timely and appropriate NTRK fusion testing in order to inform optimal therapeutic decision-making; and Apply best practices for collaboration and coordination of care with multidisciplinary colleagues for patients with NTRK fusion–positive thyroid cancer, including appropriate integration of TRK-targeted therapies into treatment plans and recognition/management of treatment-related adverse events.

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease Oct 04, 2022

Show notes

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Steven E. Carsons, MD - Expert Perspectives on Novel Targeted Therapies for Sjögren’s Disease: Hope Is on the Horizon Oct 04, 2022

Show notes

Go online to PeerView.com/HPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss the pathology of Sjögren's disease and potential treatment targets, as well as the clinical criteria and biomarkers used to diagnose the disease and aid in patient classification. Upon completion of this activity, participants should be better able to: Recognize the burden of disease, impact on quality of life, and unmet needs experienced by patients with Sjögren's disease; Describe the pathology of Sjögren's disease and potential treatment targets; Apply clinical criteria, guidelines, and biomarkers to diagnose Sjögren's disease and aid in patient classification; and Identify patients who may derive benefit from novel therapeutic options for Sjögren's disease using clinical trial data and shared decision-making.

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief Sep 27, 2022

Show notes

Go online to PeerView.com/CYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation. You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options. Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction. Upon completion of this activity, participants should be better able to: Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC; Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents; and Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care.

Jeffrey L. Neul, MD, PhD - Encouraging News in Rett Syndrome: Steps Towards a Timely, Accurate Diagnosis and Treatment Breakthroughs Sep 22, 2022

Show notes

Go online to PeerView.com/QSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Rett syndrome discusses the diagnosis and management of this rare disease, as well as the latest data on emerging treatment options. A 3D animation offers an overview of MECP2 mutation, hypothesized to be a major contributor to the CNS manifestations of Rett syndrome. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in infants demonstrating subtle signs and symptoms; Implement consensus recommendations on the age-specific management of patients with Rett syndrome; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of emerging pharmacologic treatment options to consider implementing these novel therapies when they become available.

Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies Sep 22, 2022

Show notes

Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

David Staskin, MD - Controlling the Urgency Emergency, Restoring QOL: Safe and Effective Management of Overactive Bladder Sep 19, 2022

Show notes

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC Sep 19, 2022

Show notes

Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences.